First patient dosed in Phase II OCULE-01 study with roginolisib, an allosteric modulator of PI3Kδ The European Medicines Agency (EMA) has granted Orphan Drug Designation for roginolisib for treatment of uveal melanoma – benefits include 10 years market exclusivity in the European Union Geneva, Switzerland and Amsterdam, The Netherlands, 20 March 2025 – iOnctura, a […]
Signadori Bio, a novel cell therapy platform, emerges from collaboration with scientific founders Dr. Jean-Luc Perfettini and Professor Nathalie Chaput PARIS, France – March 18, 2025 — Sofinnova Partners, a leading European life sciences venture capital firm, in collaboration with Gustave Roussy, Europe’s leading cancer center, announces the creation of their first pioneering biotech company. […]
Elizabeth Holt, with a proven track record of forging successful life sciences partnerships, appointed as Chief Business Officer (CBO) Dr Mark Velleca appointed as Board Chair, bringing considerable experience in company building and drug development Geneva, Switzerland and Amsterdam, The Netherlands, 17 March 2025 – iOnctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, […]
Robert Tighe appointed as Senior Vice President of Preclinical and Translational Sciences and Katherine Bell-McGuinn, M.D., Ph.D. appointed as Senior Vice President of Clinical Development Appointments support Ottimo Pharma as it rapidly advances the clinical development of lead candidate, Jankistomig, its first-in-class dual pathway, biparatopic IgG1 therapy IND clearance for Jankistomig is on track for […]
Dr. Aleix Prat, an internationally recognized leader in drug and biomarker development appointed Chair of the Advisory Board Dr. Jutta Amersdorffer appointed as Chief Medical Officer and Stéphane Durant des Aulnois appointed as Chief Financial Officer Accelerating development of first-in-class ADCs in multiple large solid tumor types designed against novel targets with a focus on […]
